Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies

Supportive Care in Cancer

Volumn 11, Issue 4, 2003, Pages 226-231

  Nieuw Amerongen, A V ^a   Veerman, E C I ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Hyposalivation; Mouthwashes; Saliva substitutes; Xerostomia

Indexed keywords

ACID; ANETHOLE TRITHIONE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETHANECHOL; BICARBONATE; BROMHEXINE; CARBACHOL; CARBOXYMETHYLCELLULOSE; CEVIMELINE; CHOLERETIC AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CITRIC ACID; ENZYME; GLYCEROL; MENTHOL; MUCOLYTIC AGENT; MUSCARINIC AGENT; PHYSOSTIGMINE; PILOCARPINE; POLYACRYLIC ACID; POLYMER; SALIVA SUBSTITUTE; SODIUM CHLORIDE; THICKENING AGENT; TOOTHPASTE; UNINDEXED DRUG; WATER; XANTHAN;

ACUPUNCTURE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CHEWING GUM; DENTAL CARIES; HEAD AND NECK CANCER; HUMAN; LEMON; LUBRICATION; MALIGNANT NEOPLASTIC DISEASE; MOUTH HYGIENE; MOUTH INFLAMMATION; NAUSEA; PREVENTIVE DENTISTRY; PRIORITY JOURNAL; RADIATION INJURY; REVIEW; SALIVARY GLAND DISEASE; SALIVATION; SIDE EFFECT; SWEATING; XEROSTOMIA;

EID: 0038274706     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-002-0409-5     Document Type: Review

References (45)

1. Arisawa H, Imai E, Fujise N, Fukui K, Masunaga H (2002) General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1. Effects on general behavior and central nervous system. Drug Res 52:14-20
2. Arisawa H, Fukui K, Fujise N, Masunaga H (2002) General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2. Effects on somatic nervous sytem and on autonomic nervous system and smooth muscle. Drug Res 52:81-88
3. Arisawa H, Fukui K, Masunaga H (2002) General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3. Effects on respiratory and cardiovascular systems. Drug Res 52:162-167
4. Asari T, Komatsu Y, Misawa K, Hara K, Akahane M (2001) Prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by X-ray irradiation in rats. Clin Exp Pharmacol Physiol 28:545-550
5. Bernardi R, Perin C, Becker FL, Ramos GZ, Gheno GZ, Lopes LR, Pires M, Barros HMT (2002) Effect of pilocarpine mouthwash on salivary flow. Braz J Med Biol Res 35:105-110
6. Blom M, Lundeberg T (2000) Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 6:15-24
7. Blom M, Dawidson I, Fernberg JO, Johnson G, Angmar-Mansson B (1996) Acupuncture treatment of patients with radiation-induced xerostomia. Eur J. Cancer [B Oral Oncol] 32:182-190
8. Bohuslavizki KH, Brenner W, Hubner RH, Lassmann S, Klutmann S, Feyerabend B, Luttges J, Tinnemeyer S, Clausen M, Henze E (1998) Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med 39:1237-1242
9. Davies AN (2000) A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Palliat Med 14:197-203
10. Davies AN, Broadley K, Beighton D (2001) Xerostomia in patients with advanced cancer. J Pain Symptom Manage 22:820-825
11. Dawidson I, Angmar-Mansson B, Blom M, Theodorsson E, Lundeberg T (1998) Sensory stimulation (acupuncture) increases the release of vasoactive intestinal polypeptide in the saliva of xerostomia sufferers. Neuropeptides 32:543-548
12. Ekström J, Helander HF (2002) Secretion from submucosal salivary glands of the ferret in response to a cholinesterase inhibitor applied onto the oral mucosa. Eur J Oral Sci 110:230-236
13. Epstein JB, Emerton S, Le ND, Stevenson-Moore P (1999) A doubleblind crossover trial of Oral Balance gel and Biotène toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 35:132-137
14. Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, Suen JY (2002) Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome a randomized trial. Arch Intern Med 162:1293-1300
15. Grisius MM (2001) Salivary gland dysfunction: a review of systemic therapies. Oral Surg Oral Med Oral Pathol Oral Rad Endod 92:156-162
16. Guchelaar H-J, Vermes A, Meerwaldt JH (1997) Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5:281-288
17. Hedner E, Birkhed D, Hedner J, Ekström J, Helander HF (2001) Stimulation of minor salivary glands by intraoral treatment with the cholinesterase inhibitor physostigmine in man. Eur J Oral Sci 109:371-374
18. Helmerhorst EJ, Van 't Hof W, Veerman ECI, Simoons-Smit I, Nieuw Amerongen AV (1997) Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochem J 326:39-45
19. Hof W Van 't, Veerman ECI, Helmerhorst EJ, Nieuw Amerongen AV (2001) Antimicrobial peptides: properties and applicability. Biol Chem 362:597-619
20. Jansma J, Vissink A, Spijkervet FKL, Roodenburg JLN, Panders AK, Vermey A, Szabo BG, 's-Gravenmade EJ (1992) Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 70:2171-2180
21. Jellema AP, Langendijk H, Bergenhenegouwen L, Van der Reijden W, Leemans R, Smeele L, Slotman BJ (2000) The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiother Oncol 59:157-160
22. Jones RE, Takeuchi T, Eisbruch A, D'Hondt E, Hazuka M, Ship JA (1996) Ipsilateral parotid sparing study in head and neck cancer patients which receive radiation therapy. Results after one year. Oral Surg Oral Med Oral Pathol 81:642-648
23. Licht R, Kampinga HH, Coppes RP (2002) Salivary gland-sparing prophylactic pilocarpine treatment has no effect on tumor regrowth after irradiation. Radiat Res 157:596-598
24. Mickels N, McManus C, Massaro J, Friden P, Braman V, D'Agostino R, Oppenheim F, Warbington M, Dibart S, Van Dyke T (2001) Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis. J Clin Periodontol 28:404-410
25. Miller M, Kearney N (2001) Oral care for patients with cancer: a review of the literature. Cancer Nurs 24:241-254
26. Momm F, Müller M, Tsekos A, Guttenberger R (2001) Xerostomie nach Strahlentherapie. Effektivere Behandlung durch ein mucinhaltiges Spray? HNO 49:831-836
27. Nagano T, Takeyama M (2001) Enhancement of salivary secretion and neuropeptide (substance P, α-calcitonin gene-related peptide) levels in saliva by chronic anethole trithione treatment. J Pharm Pharmacol 53:1697-1702
28. Nieuw Amerongen AV, Oderkerk CH, Driessen AA (1987) Role of mucins from human whole saliva in the protection of tooth enamel against demineralization in vitro. Caries Res 21:297-309
29. Nieuw Amerongen AV, Veerman ECI (2002) Saliva - the defender of the oral cavity. Oral Dis 8:12-22
30. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P (2002) A double-blind, randomized, placebocontrolled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46:748-754
31. Regelink G, Vissink A, Reintsema H, Nauta JM (1998) Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int 29:383-388
32. Reijden WA van der, Kwaak JS van der, Vissink A, Veerman ECI, Nieuw Amerongen AV (1996) Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren's syndrome. Arthritis Rheum 39:57-63
33. Ripamonti C, Zecca E, Brunelli C, Fulfaro F, Villa S, Balzarini A, Bombardieri E, de Conno F (1998) A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 82:1938-1945
34. Roesink JM, Terhaard CHJ (2002) The influence of clinical factors on human stimulated parotid flow rate in cancer and other patients. Oral Oncol 38:291-295
35. Rothstein DM, Spacciapoli P, Tran LT, Xu T, Roberts FD, Dalla Serra M, Buxton DK, Oppenheim FG, Friden P (2001) Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrob Agents Chemother 45:1367-1373
36. Ruissen ALA, Reijden WA van der, Van 't Hof W, Veerman ECI, Nieuw Amerongen AV (1999) Evaluation of the use of xanthan as vehicle for cationic antifungal peptides. J Control Release 60:49-56
37. Ruissen ALA, Groenink J, Lommerse CH, Van 't Hof W, Veerman ECI, Nieuw Amerongen AV (2002) Effect of carbohydrate polymers applicable in saliva substitutes on the anti-Candida activity of a histatin-derived peptide. Arch Oral Biol (in press)
38. Schiødt M, Hermund NU (2002) Management of oral disease prior to radiation therapy. Support Care Cancer 10:40-43
39. Senn HJ (1997) Orphan topics in supportive care: how about xerostomia? Support Care Cancer 5:261-262
40. Shaw MJ, Kumar NDK, Duggal M, Fiske J, Lewis DA, Kinsella T, Nisbet T (2000) Oral management of patients following oncology treatment: literature review. Br J Oral Maxillofac Surg 38:519-524
41. Sonis ST, Fey EG (2002) Oral complications of cancer therapy. Oncology 16:680-686
42. Taylor SE, Miller EG (1999) Pre-emptive pharmacologic intervention in radiation-induced salivary dysfunction. Proc Soc Exp Biol Med 221:14-26
43. Vissink A, Schaub RMH, Van Rijn LJ, 's-Gravenmade EJ, Panders AK, Vermey A (1987) The efficacy of mucin-containing artificial saliva in alleviating symptoms of xerostomia. Gerodontology 6:95-101
44. Vivino FB (2001) The treatment of Sjögren's syndrome patients with pilocarpine-tablets. J Rheumatol 115:1-13
45. Yasuda H, Niki H (2002) Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with Sjögren's syndrome. Clin Drug Invest 22:67-73